Skip to main content
main-content

08-06-2020 | ASCO 2020 | Conference coverage | Video

Expert highlights: Targeted therapy for ALK-, RET- and MET-driven NSCLC

Tejas Patil rounds up findings from the ALEX, ALTA-1L, ARROW, LIBRETTO-001, GEOMETEY mono-1 and VISION studies of non-small-cell lung cancer patients with ALK, RET, or MET alterations (9:56).

Read transcript

Enriched treatment pathway for non-driver NSCLC

What is it and why do I need it?

Have your say on Medicine Matters

Visit the conference hub

Image Credits